Sugeruję, żebyście podzielili te posty na osobne FAQs.

Serio potrzebne te posty wyżej kopiuj/wklej prosto z jakichś randomowych stron o lekach?

[mention]A-CoA[/mention] Ta część nie jest już mojego autorstwa, więc może [mention]wnc1964[/mention] utworzysz osobny wątek tak, jak radziła [mention]misspill[/mention]?

No dobrze jak chcecie , chciałem pomóc bo kto np słyszał o takim antydepresancie jak Melitracen, jedynie opis neuroleptyków jest do dupy o SSRI pisałem z głowy używając czasami swoje odczucia, w każdym razie dziękuję za początkową ofertę przepraszam i pozdrawiam.

Wnc, zrób swoją część FAQ, zapraszam Cię do współpracy, zobacz jak ładnie edytowałam Twoje opracowanie w (przed)ostatnim poście.

misspill bardzo ładnie zrobiłaś :-) wielkie dzięki.

Jak znajdę trochę czasu zrobię własne część FAQ , mogę cię tylko prosić do zaglądniecia czasami i edytacji bo fajnie to robisz.
Co do mojej częśći FAQ napewno opis SSRI będzie wyglądał podobnie leki stosowane kiedyś też lub często pomijane , też choć może uda mi się może dać kilka opisów więcej w książkach trochę tego jest.

Jest kilka ktorych nie wymieniono:

reuptake inhibitors and/or receptor modulators
SSRIs
citalopram Escitalopram Fluoxetine# Fluvoxamine Indalpine‡ Paroxetine Sertraline Zimelidine‡

SNRIs
Desvenlafaxine Duloxetine Levomilnacipran Milnacipran Tofenacin Venlafaxine

NRIs
Atomoxetine Reboxetine Viloxazine

NDRIs
Amineptine‡ bupropion Nomifensine‡

NaSSAs
Mianserin Mirtazapine Setiptiline

SARIs
Etoperidone Nefazodone Trazodone

SMS
Vilazodone Vortioxetine

Others
Agomelatine Amisulpride Esketamine† Etryptamine‡ Indeloxazine flupentixol Ketamine† Medifoxamine‡ Metryptamine‡ Oxaflozane‡ Pivagabine‡ Tandospirone Teniloxazine Tianeptine

Tricyclic and tetracyclic antidepressants

TCAs
Amineptine‡ Amitriptyline# Amitriptylinoxide Butriptyline‡ Clomipramine# Demexiptiline‡ Desipramine Dibenzepin Dimetacrine‡ Dosulepin Doxepin Imipramine Imipraminoxide‡ Iprindole‡ Lofepramine Melitracen Metapramine‡ Nitroxazepine Nortriptyline Noxiptiline Opipramol Pipofezine Propizepine‡ Protriptyline Quinupramine‡ Tianeptine Trimipramine

TeCAs
Amoxapine Maprotiline Mianserin Mirtazapine Setiptiline

Others
Tiazesim

Monoamine oxidase inhibitors

Non-selective
Irreversible: Benmoxin‡ Iproclozide‡ Iproniazid‡ Isocarboxazid Isoniazid# Linezolid# Mebanazine‡ Nialamide‡ Octamoxin‡ Phenelzine Pheniprazine‡ Phenoxypropazine‡ Pivhydrazine‡ Safrazine‡ Tedizolid Tranylcypromine

Reversible: Caroxazone‡

Mixed: Bifemelane

MAOA-selective
Reversible: Eprobemide Metralindole Minaprine‡ Moclobemide Pirlindole Tetrindole Toloxatone

MAOB-selective
Irreversible: Selegiline

Never marketed
Antidepressants
Alaproclate (GEA-654)
Centpropazine
Cericlamine (JO-1017)
Femoxetine (Malexil; FG-4963)
Ifoxetine (CGP-15210)
Omiloxetine
Panuramine (WY-26002)
Pirandamine (AY-23713)
Seproxetine ((S)-norfluoxetine
--'--

Niektore badaja:

Glutamatergics
NMDA receptor modulators
4-Chlorokynurenine (AV-101) – NMDA receptor glycine site antagonist[1]
AGN-241751 – NMDA receptor modulator[2][3]
Apimostinel (NRX-1074) – NMDA receptor glycine site partial agonist
Esketamine (JNJ-54135419, Ketanest S) – non-competitive NMDA receptor antagonist
EVT-101 (ENS-101) – NR2B antagonist
EVT-103 (ENS-103) – NR2B antagonist
Ketamine (Ketalar) – non-competitive NMDA receptor antagonist
Rapastinel (GLYX-13) – NMDA receptor glycine site partial agonist
Rislenemdaz (CERC-301, MK-0657) – NMDA receptor subunit 2B (NR2B) antagonist

Others
Basimglurant (RG-7090) – mGluR5 negative allosteric modulator
Tulrampator (S-47445, CX-1632) – AMPA receptor positive allosteric modulator

Monoaminergics
Monoamine reuptake inhibitors
AN-788 (NSD-788) – serotonin–dopamine reuptake inhibitor (SDRI)[15]
Ansofaxine (LY03005, LPM570065) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI)
PDC-1421 (BLI-1005) – norepinephrine reuptake inhibitor (NRI)
Monoamine reuptake inhibitors and receptor modulators
MIN-117 (WF-516) – SDRI, 5-HT1A receptor antagonist, 5-HT2A, α1A-adrenergic, and α1B-adrenergic receptor ligand
TGBA01AD (FKB01MD) – serotonin reuptake inhibitor (SRI), 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist

Monoamine receptor modulators
Gepirone (TGFK07AD; Travivo) – 5-HT1A receptor partial agonist
Pimavanserin (Nuplazid; ACP-103; BVF-048) – 5-HT2A receptor antagonist
Psilocybin – non-selective serotonin receptor agonist

Atypical antipsychotics
Aripiprazole/sertraline (ASC-01) – atypical antipsychotic (AA) and selective serotonin reuptake inhibitor (SSRI) combination
Cariprazine (Vraylar) – AA – specifically under development for the adjunctive treatment of MDD and as a monotherapy for depressive episodes in bipolar disorder
Lumateperone (ITI-007) – AA – specifically under development for the treatment of depressive episodes in bipolar disorder
Lurasidone (Latuda) – AA – specifically under development for the treatment of MDD
RP-5063 (RP-5000) – AA – specifically under development for the treatment of MDD and depressive episodes in bipolar disorder

Others
Ademetionine (SAMe; MSI-190, MSI-195, Strada) – cofactor in monoamine neurotransmitter biosynthesis – specifically under development in the United States and Europe for the adjunctive treatment of MDD

Neurosteroids
GABAA receptor positive modulators
Brexanolone (allopregnanolone; SAGE-547) – GABAA receptor positive allosteric modulator – specifically under development for the treatment of postpartum depression
Ganaxolone (CCD-1042) – GABAA receptor positive allosteric modulator – specifically under development for the treatment of postpartum depression
SAGE-217 – GABAA receptor positive allosteric modulator – specifically under development for the treatment of both MDD and postpartum depression

Others
3β-Methoxypregnenolone (MAP-4343) – selective microtubule-associated protein 2 (MAP2) stimulant
PH-10 – vomeropherine (precise mechanism of action unknown/undisclosed)

Opioidergics
κ-Opioid receptor antagonists
Buprenorphine/samidorphan (ALKS-5461) – κ-opioid receptor antagonist
CERC-501 (LY-2456302) – κ-opioid receptor antagonist

Others
BTRX-246040 (LY-2940094) – nociceptin receptor antagonist

Others
JNJ-39393406 – α7 nicotinic acetylcholine receptor positive allosteric modulator
JNJ-54175446 – P2RX7 purinoceptor antagonist
NNI-351 – DYRK1A inhibitor/"nerve growth factor stimulant"
NSI-189 – hippocampal neurotrophic agent (precise mechanism of action unknown)
NV-5138 – sestrin2 modulator and consequent mammalian target of rapamycin complex 1 (mTORC1) activator
OnabotulinumtoxinA (botulinum toxin A, Botox) – acetylcholine release inhibitor – specifically under development for the treatment of MDD in women as a local injection to paralyze facial muscles
Seltorexant (MIN-202, JNJ-42847922, JNJ-922) – OX2 receptor antagonist[45]
Sirukumab (CNTO-136) – monoclonal antibody against interleukin-6[46]
SUVN-911 – α4β2 nicotinic acetylcholine receptor antagonist or negative allosteric modulator[47]
TS-121 – vasopressin 1B receptor antagonist

Mixed
tramadol (ETS6103; Viotra) – μ-opioid receptor agonist, serotonin–norepinephrine reuptake inhibitor (SNRI) and possible serotonin releasing agent (SRA), 5-HT2C receptor antagonist, and other actions

Combinations
bupropion/dextromethorphan (AXS-05) – σ1 receptor agonist, SNRI, non-competitive nicotinic acetylcholine receptor antagonist, uncompetitive NMDA receptor antagonist, and other actions
Cycloserine/lurasidone (Cyclurad) – NMDA receptor glycine site partial agonist and AA combination – specifically under development for the treatment of depressive episodes in bipolar disorder
Dextromethorphan/quinidine (AVP-786/AVP-923) – σ1 receptor agonist, SNRI, uncompetitive NMDA receptor antagonist, and other actions
Not under development
The following drugs are currently of major investigational interest as potential antidepressants but are not formally under clinical development for approval at this time:

7,8-Dihydroxyflavone (7,8-DHF) – TrkB agonist[
Hydroxynorketamine ((2R,6R)-HNK) – metabolite of ketamine which may be involved in ketamine's antidepressant-like effects in mice
Minocycline – microglia inhibitor and other actions; a 2018 systematic review and meta-analysis reported that the overall antidepressant effect size of minocycline compared to placebo was -0.78 (95% CI: -0.4 to -1.33, P=0.005), indicative of a large and statistically significant antidepressant effect[65][66]
Nitrous oxide – NMDA receptor antagonist and other actions
Pramipexole – partial or full agonist of the D2, D3, and D4 receptors
R13 – an orally active prodrug of 7,8-DHF with improved pharmacokinetics

[mention]Stteetart[/mention] Oczywiście, jest ich mnóstwo, więc skupiłam się na tych zarejestrowanych w Polsce i najczęściej stosowanych w leczeniu depresji.

Dziewczyny narazie i tak bardzo dobrze wam idzie :-)

Bupro potrafi działać od pierwszej tabletki (honeymoon).